Ridge Bio

Ridge Bio is a private, AI-native biotech emerging from stealth with a $25M seed round to pioneer precision enzyme and targeted drug design. Its core platform combines generative AI with high-throughput wet-lab experimentation to solve complex bioconjugation and delivery challenges, enabling the development of novel therapeutics like ADCs, enzyme-based drugs, and targeted delivery systems. With a strong founding team and a prestigious scientific advisory board, the company is positioned to partner with drug developers to create differentiated medicines with improved therapeutic indices. Its initial product focus is on its NativeLink enzyme platform for site-specific bioconjugation and ProTrigger linkers for conditional payload activation.

Proprietary machine learning models integrated with high-throughput, cell-free wet-lab experimentation for the design of precision enzymes, conditionally activated linkers, and targeted delivery systems.

Ridge Bio competes with other AI-driven protein design companies (e.g., Absci, Generate Biomedicines) and specialized bioconjugation firms. Its unique integration of cell-free data generation and a focus on enzymatic conjugation and conditional linkers may differentiate it. However, it must contend with established chemistry-based conjugation methods and large biopharma internal R&D efforts.